Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

Basu, B.; Krebs, Matthew G.; Sundar, R.; Wilson, R. H.; Spicer, J.; Jones, R.; Brada, M.; Talbot, D. C.; Steele, N.; Ingles Garces, A. H.; Brugger, W.; Harrington, E. A.; Evans, J.; Hall, E.; Tovey, H.; de Oliveira, F. M.; Carreira, S.; Swales, K.; Ruddle, R.; Raynaud, F. I.; Purchase, B.; Dawes, J. C.; Parmar, M.; Turner, A. J.; Tunariu, N.; Banerjee, S.; de Bono, J. S.; Banerji, U.

Published in

Elsevier, Annals of Oncology, 9(29), p. 1918-1925, 2018

DOI: 10.1093/annonc/mdy245

Tools

Export citation

Search in Google Scholar

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

Journal article published in 2018 by B. Basu, Matthew G. Krebs, R. Sundar, R. H. Wilson, J. Spicer, R. Jones, M. Brada, D. C. Talbot, N. Steele, A. H. Ingles Garces, W. Brugger, E. A. Harrington, J. Evans, E. Hall, H. Tovey and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Abstract

We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.

Published in

Links

Tools

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer.

Abstract